Human CD30 Recombinant Rabbit Monoclonal Antibody [PSH04-81] - BSA and Azide free (Capture)
Antibody Type
Recombinant Rabbit monoclonal Antibody
Immunogen
Recombinant protein within Human CD30 aa 19-385 (P28908).
Species Reactivity
Human
Validated Applications
ELISA(Cap)
Target Molecular Weight
Predicted band size: 64 kDa
Positive Control
Recombinant Human CD30 protein (HA210649).
Conjugation
unconjugated
Clone Number
PSH04-81
Product Features
Form
Liquid
Concentration
1 mg/mL.(The concentration of this product may be batch-dependent)
Lot Concentration Lookup
Storage Instructions
Store at 2-8℃. Avoid freeze.
Storage Buffer
PBS (pH7.4).
Isotype
IgG
Purification Method
Protein A affinity purified.
Application Dilution
ELISA(Cap)
Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit monoclonal [PSH04-82] to Human CD30 (Detector) (HA722188) and recombinant standard Human CD30 protein (HA210649). The reference range value is 31-2,500 pg/mL.
Target
Function
CD30, also known as TNFRSF8 (TNF receptor superfamily member 8), is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.
Background References
1. Horwitz S et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022 Mar
2. Ramos CA et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov
Sandwich ELISA analysis of human CD30 matched pair antibodies
Elisa assay was performed by coating wells of a 96-well plate with 50 µl per well of capture antibody (HA722187) diluted in carbonate/bicarbonate buffer, at a concentration of 2 µg/mL overnight at 4℃. Wells of the plate were washed, blocked with 150 µl 0.05% tween-20 1%BSA blocking buffer, and incubated with serial diluted Recombinant Human CD30 protein (HA210649) starting from 2,000 pg/ml to 0 pg/ml and detect antibody (HA722188) (Biotin, 0.2 µg/ml) for 1 hour at 30℃ with shaking. Then the plate was washed and incubated with 50 µl per well of SA-HRP for 0.5 hour at 30℃ with shaking. Detection was performed using an Ultra TMB Substrate for 10 minutes at room temperature in the dark. The reaction was stopped with sulfuric acid and absorbances were read on a spectrophotometer at 450 nm.
The concentrations of CD30 were interpolated from the CD30 standard curves and corrected for sample dilution. Undiluted samples are HDLM-2 cell culture supernatant 50%. The mean CD30 concentration was determined to be 1,260 pg/ml in HDLM-2 cell culture supernatant.
The concentrations of CD30 were interpolated from the CD30 standard curves and corrected for sample dilution. Undiluted samples are mixed serum from twenty-four volunteers 13%. The mean CD30 concentration was determined to be 11,531 pg/ml in mixed serum from twenty-four volunteers.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"